nach oben

Current Bladder Dysfunction Reports

Erschienen in:

01.12.2014 | Geriatric Bladder Dysfunction (G Ghoniem, Section Editor)

Bladder Outlet Obstruction and BPH

verfasst von: Thomas R. Jarvis, Bilal Chughtai, Steven A. Kaplan

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

It is well known that age is the major risk factor for benign prostatic hyperplasia (BPH). A histologic diagnosis of BPH will develop in approximately half of men over 40. Of these men, approximately 50 % will develop notable lower urinary tract symptoms (LUTS), which increase in prevalence between age 40 and 80 [1]. The degree of prostatic enlargement, which impacts the severity of symptoms experienced, is highly variable. The presence of lower urinary tract symptoms is often indicative of bladder outlet obstruction (BOO) secondary to BPH, especially in the elderly. The treatment of BPH, which includes medical, minimally invasive, and surgical therapies, aims to improve subjective symptoms and quality of life. This review focuses on novel therapies for BOO secondary to BPH in the elderly.

McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5):112.

Abrams P. New words for old: lower urinary tract symptoms for “prostatism”. BMJ. 1994;308(6934):929–30.PubMedCentralPubMedCrossRef

Silverman WM. “Alphabet soup” and the prostate: LUTS, BPH, BPE, and BOO. J Am Osteopath Assoc. 2004;104(2 Suppl 2):S1–4.PubMed

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.PubMed

Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980;14(1):29–35.PubMedCrossRef

Franks LM. Benign nodular hyperplasia of the prostate; a review. Ann R Coll Surg Engl. 1953;14(2):92–106.PubMed

Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health. 2013;31(2):103–25. doi:10.5534/wjmh.2013.31.2.103.PubMedCentralPubMedCrossRef

Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014. doi:10.1007/s40618-014-0051-3.PubMed

Lim CS, Abrams P. The Abrams-Griffiths nomogram. World J Urol. 1995;13(1):34–9.PubMedCrossRef

10.

Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int. 1999;84(1):14–5.PubMedCrossRef

11.

Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spangberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn. 1997;16(1):1–18.PubMedCrossRef

12.

Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J, International SC. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181(4):1779–87. doi:10.1016/j.juro.2008.11.127.PubMedCrossRef

13.

Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—focus on the UK. BJU Int. 2014. doi:10.1111/bju.12745.PubMed

14.

Tsang KK, Garraway WM. Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Ageing. 1994;23(5):360–4.PubMedCrossRef

15.

Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol. 2014;65(2):389–98. doi:10.1016/j.eururo.2013.10.015.PubMedCrossRef

16.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.PubMedCrossRef

17.•

Kalisch Ellett LM, Pratt NL, Barratt JD, Rowett D, Roughead EE. Risk of medication-associated initiation of oxybutynin in elderly men and women. J Am Geriatr Soc. 2014;62(4):690–5. This is important specifically for the elderly because it highlights the potential for commonly used medications to contribute to urinary incontinence, as well as the need for additional research and better treatment options. PubMedCrossRef

18.

Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101 Suppl 3:17–21. doi:10.1111/j.1464-410X.2008.07497.x.PubMedCrossRef

19.•

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-–40. doi:10.1016/j.eurouro.2013.03.004. Presents the most up-to-date guidelines on the treatment of male LUTS.PubMedCrossRef

20.

Maserejian NN, Chen S, Chiu GR, Araujo AB, Kupelian V, Hall SA, et al. Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. J Urol. 2014;191(1):107–13. doi:10.1016/j.juro.2013.07.005.PubMedCentralPubMedCrossRef

21.

Chen Y, Zhang X, Hu X, Deng Y, Chen J, Li S, et al. The potential role of a self-management intervention for benign prostate hyperplasia. Urology. 2012;79(6):1385–8. doi:10.1016/j.urology.2011.11.091.PubMedCrossRef

22.

Yap TL, Brown C, Cromwell DA, van der Meulen J, Emberton M. The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int. 2009;104(8):1104–8. doi:10.1111/j.1464-410X.2009.08497.x.PubMedCrossRef

23.

Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843–53.PubMedCrossRef

24.

Kashyap M, Tu LM, Tannenbaum C. Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence. BMC Geriatr. 2013;13(1):57. doi:10.1186/1471-2318-13-57.PubMedCentralPubMedCrossRef

25.

Barendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int. 2005;95 Suppl 4:19–28. doi:10.1111/j.1464-410X.2005.05487.x.PubMedCrossRef

26.

Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013;347:f6320. doi:10.1136/bmj.f6320.PubMedCentralPubMedCrossRef

27.•

Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology. 2011;118(4):730–5. doi:10.1016/j.ophtha.2010.08.039. Focuses on a potential side effect of alpha-blockers that patients should be aware of.PubMedCrossRef

28.

Hargitai J, Vezendi L, Vigstrup J, Eisgart F, Lundbye-Christensen S, Hargitai B, et al. Comparing the efficacy of mydriatic cocktail-soaked sponge and conventional pupil dilation in patients using tamsulosin—a randomized controlled trial. BMC Ophthalmol. 2013;13:83. doi:10.1186/1471-2415-13-83.PubMedCentralPubMedCrossRef

29.

Lorente R, de Rojas V, Vazquez de Parga PV, Moreno C, Varela J, Landaluce ML, et al. Intracameral phenylephrine 1.5 % for prophylaxis against intraoperative floppy iris syndrome: prospective, randomized fellow eye study. Ophthalmology. 2012;119(10):2053–8.

30.

McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557–63. doi:10.1056/NEJM199802263380901.PubMedCrossRef

31.

McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98. doi:10.1056/NEJMoa030656.PubMedCrossRef

32.

Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17–25. doi:10.1016/j.clinthera.2007.01.018.PubMedCrossRef

33.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24. doi:10.1056/NEJMoa030660.PubMedCrossRef

34.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202. doi:10.1056/NEJMoa0908127.PubMedCrossRef

35.

Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554–66. doi:10.1111/jsm.12525.PubMedCrossRef

36.

Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12(1):81–90. doi:10.1517/14740338.2013.742885.PubMedCrossRef

37.

Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31. doi:10.1016/j.eururo.2009.09.035.PubMedCrossRef

38.

Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461–6.PubMedCrossRef

39.

Nickel JC, Barkin J, Koch C, Dupont C, Elhilali M. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J. 2008;2(1):16–21.PubMedCentralPubMed

40.

Yassin DJ, El Douaihy Y, Yassin AA, Kashanian J, Shabsigh R, Hammerer PG. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol. 2013. doi:10.1007/s00345-013-1187-z.PubMed

41.

Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28. doi:10.1001/jama.296.19.2319.PubMedCrossRef

42.

Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009;182(6):2825–30. doi:10.1016/j.juro.2009.08.023.PubMedCrossRef

43.

Abrams P, Kaplan S, De Koning GH, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 Pt 1):999–1004.PubMedCrossRef

44.

Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169(6):2253–6.PubMedCrossRef

45.

Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update Arch Intern Med. 1997;157(14):1531–6.CrossRef

46.

Kraus SR, Bavendam T, Brake T, Griebling TL. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging. 2010;27(9):697–713. doi:10.2165/11539020-000000000-00000.PubMedCrossRef

47.

Otsuki H, Kosaka T, Nakamura K, Mishima J, Kuwahara Y, Tsukamoto T. Beta 3 adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53–60.PubMedCrossRef

48.

Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;9:CD004135. doi:10.1002/14651858.CD004135.pub3.PubMed

49.

Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, et al. Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014;113(4):615–22. doi:10.1111/bju.12540.PubMedCrossRef

50.

Somani BK, Hacking N, Bryant T, Coyne J, Flowers D, Harris M, et al. Prostate artery embolization (PAE) for benign prostatic enlargement (BPE). BJU Int. 2014. doi:10.1111/bju.12672.

51.

Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, Morgia G, et al. Prostatic artery embolization for prostate volume greater than 80 cm: results from a single-center prospective study. Urology. 2014. doi:10.1016/j.urology.2014.04.028.PubMed

52.

Moreira AM, Marques CF, Antunes AA, Nahas CS, Nahas SC, de Gregorio Ariza MA, et al. Transient ischemic rectitis as a potential complication after prostatic artery embolization: case report and review of the literature. Cardiovasc Intervent Radiol. 2013;36(6):1690–4. doi:10.1007/s00270-013-0739-3.PubMedCrossRef

53.

Bozkurt IH, Yalcinkaya F, Sertcelik MN, Zengin K, Ekici M, Yigitbasi O. A good alternative to indwelling catheter owing to benign prostate hyperplasia in elderly: Memotherm prostatic stent. Urology. 2013;82(5):1004–7. doi:10.1016/j.urology.2013.07.004.PubMedCrossRef

54.

Ogiste JS, Cooper K, Kaplan SA. Are stents still a useful therapy for benign prostatic hyperplasia? Curr Opin Urol. 2003;13(1):51–7. doi:10.1097/01.mou.0000049385.71470.43.PubMedCrossRef

55.

Barber NJ, Roodhouse AJ, Rathenborg P, Nordling J, Ellis BW. Ease of removal of thermo-expandable prostate stents. BJU Int. 2005;96(4):578–80. doi:10.1111/j.1464-410X.2005.05687.x.PubMedCrossRef

56.

Armitage JN, Rashidian A, Cathcart PJ, Emberton M, van der Meulen JH. The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review. BJU Int. 2006;98(4):806–10. doi:10.1111/j.1464-410X.2006.06399.x.PubMedCrossRef

57.

Kimata R, Nemoto K, Tomita Y, Takahashi R, Hamasaki T, Kondo Y. Efficacy of a thermoexpandable metallic prostate stent (Memokath) in elderly patients with urethral obstruction requiring long-term management with urethral Foley catheters. Geriatr Gerontol Int. 2014. doi:10.1111/ggi.12309.PubMed

58.

Devonec M, Dahlstrand C. Temporary urethral stenting after high-energy transurethral microwave thermotherapy of the prostate. World J Urol. 1998;16(2):120–3.PubMedCrossRef

59.

Brierly RD, Mostafid AH, Kontothanassis D, Thomas PJ, Fletcher MS, Harrison NW. Is transurethral resection of the prostate safe and effective in the over 80-year-old? Ann R Coll Surg Engl. 2001;83(1):50–3.PubMedCentralPubMed

Titel: Bladder Outlet Obstruction and BPH
verfasst von: Thomas R. Jarvis
Bilal Chughtai
Steven A. Kaplan
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 4/2014
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-014-0263-6

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Long-Term Complications of the Irradiated Bladder: a Review

Prevention of Urinary Tract Infection for Patients with Neurogenic Bladder

Long-Term Enterocystoplasty Follow-Up: Metabolic and Neoplastic Concerns

Stress Urinary Incontinence in the Elderly: Evaluation, Surgical Treatment, and Management of Postoperative Voiding Dysfunction